PURPOSE: To assess the clinical results in terms of local control, @entity137 , failure pattern and @entity137 of SBRT in oligometastatic @entity1 with inoperable lung metastases. METHODS: Forty-four @entity1 were treated (53 metastases). Dose regimen: 5  *  12  Gy (66  %), 8  *  7.5  Gy (20.8  %) and 10  *  5  Gy (13.2  %). Response was assessed using PET/CT at 6  months after SBRT. RESULTS: Local control at 1 and 2  years was 86.7  %. Seventy-five percent of local failures had received a BED <105  Gy. After a median follow-up of 13.3  months, 25  % experienced distant progression. Overall survival at 1 and 2  years was 86.7 and 60.4  %, and @entity5 -specific survival was 95.3 and 75.2  %, respectively. Grade 2 @entity137 was 6.8  %. There was no grade 3-4 @entity137 . CONCLUSION: SBRT is effective and safe. The main failure pattern is distant progression. The selection of @entity1 with a high probability of remaining oligometastatic is crucial for the efficiency of SBRT, both clinically and in terms of resources.

Lung metastases in oligometastatic XXXX : outcome with stereotactic body radiation therapy (SBRT).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']
@entity1 :: (9606,Species) :: ['patients']
